New developments in diagnosis, risk assessment and management in systemic amyloidosisIuliana Vaxman, Morie A. Gertz, Angela Dispenzieri et al.|Blood Reviews|2019Cited by 50
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experienceIuliana Vaxman, Morie A. Gertz, Kristen McCullough et al.|Blood Cancer Journal|2021Cited by 49
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P. Abeykoon, Prashant Kapoor, Iuliana Vaxman et al.|British Journal of Haematology|2022Cited by 24
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agentsIuliana Vaxman, Morie A. Gertz, Alissa Visram et al.|Bone Marrow Transplantation|2020Cited by 21
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patientsAlissa Visram, Nelson Leung, Abdullah S. Al Saleh et al.|Blood Cancer Journal|2020Cited by 21